Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
Petvivo Holdings, Inc. (PETVW) is a pioneer in developing innovative biomedical devices for companion animals, leveraging human medical advancements to address veterinary health challenges. This dedicated news hub provides investors and industry professionals with essential updates on the company's progress in pet therapeutics.
Access real-time announcements covering regulatory milestones, product developments, and strategic partnerships. Our curated collection includes earnings reports, technology licensing updates, and clinical trial progress related to PETVW's portfolio of joint care solutions like the Spryng™ OsteoCushion™ system.
Key updates focus on commercialization efforts for veterinary medical devices, intellectual property expansions, and market penetration strategies. Stay informed about PETVW's unique approach to adapting human biomaterials for animal health applications through this comprehensive news resource.
Bookmark this page for direct access to verified company communications and third-party analysis. Check regularly for developments in PETVW's mission to enhance animal mobility through advanced therapeutic solutions.
PetVivo Holdings (OTCQB: PETV) has secured an Exclusive License and Supply Agreement with VetStem to commercialize PrecisePRP®, an innovative off-the-shelf platelet-rich plasma product for dogs and horses. This first-in-class product eliminates the need for blood draws or centrifugation, providing veterinarians with a consistent dose of 4 billion platelets per vial at 500,000 platelets per microliter.
The product undergoes rigorous safety screening according to FDA CVM Guidance 254, including infectious disease screening and blood type testing. Two randomized placebo-controlled safety studies revealed no treatment-related adverse events. PrecisePRP® will complement PetVivo's existing Spryng™ with OsteoCushion™ technology, reinforcing the company's position in veterinary medical devices and regenerative medicine.
PetVivo Holdings (OTCQB: PETV), a biomedical device company focused on commercializing innovative medical therapeutics for animals, has scheduled its Q3 FY2024 earnings release for Friday, February 14, 2025, after market close. The company will host a conference call and webcast to discuss the results at 2:00 p.m. CT (3:00 p.m. ET) on the same day.
Investors can access the live webcast through PetVivo's Investor Relations website, and a replay will be available following the conference call. The company has also provided dial-in details for those who prefer to join via phone.
PetVivo Holdings (OTCQB: PETV) has appointed Mike Eldred as Commercialization and Operations Advisor and Executive Director. Eldred brings 30 years of executive experience in animal health, notably serving as President of Dechra Pharmaceutical's North American Operations for 20 years, where he grew the subsidiary to over 250 employees and $400M+ in revenue.
The appointment aims to accelerate the adoption of Spryng™, PetVivo's intra-articular injectable veterinary medical device. Spryng uses OsteoCushion Technology, comprising sterilized extra-cellular matrix microparticles that integrate with animal subsynovial tissue to promote proper joint mechanics. Clinical studies have shown Spryng's effectiveness in treating lameness and joint-related conditions.
Prior to joining PetVivo, Eldred held senior positions at Virbac , Fort Dodge Animal Health, and Sanofi Animal Health, where he demonstrated success in business development, sales, and operations.
PetVivo Holdings (OTCQB: PETV) announced its participation in the Veterinary Meeting & Expo Conference from January 25-29, 2025, in Orlando, Florida. The company will showcase its flagship product, Spryng with OsteoCushion Technology, at booth #1825.
Spryng is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics. It's designed to manage noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.
VMX, the largest veterinary conference in the United States, will provide PetVivo an opportunity to demonstrate Spryng's benefits to leading veterinarian surgeons and showcase its effectiveness in treating horses and companion animals across the U.S.
PetVivo Holdings (OTCQB: PETV) has announced new distribution partnerships with Vedco Inc. and Clipper Distributing, , both major players in veterinary product distribution. These partnerships will expand the distribution network for PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, an intra-articular injectable veterinary medical device designed to manage joint pain in animals.
The partnerships connect PetVivo to major national veterinary product distributors including MWI, Covetrus, Patterson, Midwest Supply, and Penn Supply. Spryng is designed to promote joint pain management by augmenting and reinforcing cartilage to support normal joint function in cases where there is loss of cartilage or tissue-bone mechanical malfunction.
PetVivo Holdings (OTCQB: PETV and PETVW), a biomedical device company specializing in innovative medical therapeutics for animals, has announced a live webcast Shareholders Update Meeting scheduled for January 8, 2025 at 3:30 p.m. CT (4:30 p.m. ET).
The meeting will provide an overview of the company's progress in the 2025 fiscal year and discuss future prospects. Shareholders can access the webcast through PetVivo's Investor Relations website, and a replay will be available afterward. Additionally, participants can join via phone using the provided dial-in information.
PetVivo Holdings (OTCQB:PETV) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO John Lai will present a company overview and discuss their lead product, SPRYNG™ with OsteoCushion™ Technology.
SPRYNG is an intra-articular injectable veterinary medical device using sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics and manage conditions like joint instability, degenerative joint disease, and osteoarthritis.
PetVivo Holdings (OTCQB: PETV) announced its participation in the American Association of Equine Practitioners (AAEP) convention from December 8-10, 2024, in Orlando, Florida. The company will showcase Spryng™ with OsteoCushion™ Technology, their lead product for joint pain management. Spryng is an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue to restore proper joint mechanics. The product aids in managing noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.
PetVivo Holdings (OTCQB: PETV) reported fiscal Q2 2025 results with revenues of $201,000, up 62% sequentially but down 3% year-over-year. The company is transitioning from primarily equine market focus to include the larger companion animal market. Distributor sales increased 24% to $169,000. Gross profit declined 3% to $180,000, maintaining an 89.5% margin. Net loss improved to $2.2 million ($0.11 per share) compared to $3.7 million ($0.28 per share) year-ago. The company reiterated its fiscal 2025 revenue outlook of approximately $1.5 million, representing 50% growth. Cash position was $126,000 as of September 30, 2024, with additional $312,500 raised post-quarter.
PetVivo Holdings (OTCQB: PETV) announced it will release its financial results for the second quarter ended September 30, 2024, on Thursday, November 14, 2024, after market close. The biomedical device company, focused on commercializing innovative medical therapeutics for animals, will host a conference call at 4:00 p.m. CT (5:00 p.m. ET) on the same day to discuss the results. A webcast replay will be available through the company's Investor Relations website.
FAQ
What is the current stock price of Petvivo Holdings (PETVW)?
